Oxotremorine

Oxotremorine
Clinical data
Pregnancy; category	C;
Routes of; administration	Oral, intravenous
ATC code	none;
Legal status
Legal status	US: Experimental/not yet approved;
Identifiers
	IUPAC name 1-(4-Pyrrolidin-1-ylbut-2-yn-1-yl)pyrrolidin-2-one;
CAS Number	70-22-4 ;
IUPHAR/BPS	302;
ChemSpider	4469 ;
UNII	5RY0UWH1JL;
ChEMBL	ChEMBL7634 ;
CompTox Dashboard (EPA)	DTXSID10220252 ;
ECHA InfoCard	100.000.662
Chemical and physical data
Formula	C12H18N2O
Molar mass	206.289 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C1CCN(C1)CC#CCN2CCCC2=O;
	InChI InChI=InChI=1S/C12H18N2O/c15-12-6-5-11-14(12)10-4-3-9-13-7-1-2-8-13/h1-2,5-11H2 ; Key:RSDOPYMFZBJHRL-UHFFFAOYSA-N ;
	(what is this?) (verify)

Oxotremorine is a drug that acts as a selective muscarinic acetylcholine receptor agonist.^[1]

Oxotremorine produces ataxia, tremor and spasticity, similar to those symptoms seen in Parkinsonism, and has thus become a research tool in experimental studies aimed at determining more effective anti-Parkinsonian drugs.^[2]

Oxotremorine also produces antipsychotic-like effects.^[3]

References

^ Tang C, Castoldi AF, Costa LG (April 1993). "Effects of the muscarinic agonist oxotremorine on membrane fluidity in rat lymphocytes". Biochemistry and Molecular Biology International. 29 (6): 1047–54. PMID 8330013. INIST 4025194.
^ Craig CR, Stitzel RE, eds. (2004). Modern Pharmacology with Clinical Applications. Lippincott Williams & Wilkins. ISBN 978-0-7817-3762-3.^{[page needed]}
^ Maehara S, Hikichi H, Satow A, Okuda S, Ohta H (November 2008). "Antipsychotic property of a muscarinic receptor agonist in animal models for schizophrenia". Pharmacology, Biochemistry, and Behavior. 91 (1): 140–9. doi:10.1016/j.pbb.2008.06.023. PMID 18651995. S2CID 12225821. INIST 20678587.